Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas
- 1 March 1994
- journal article
- clinical trial
- Published by Wiley in Clinical Endocrinology
- Vol. 40 (3) , 421-428
- https://doi.org/10.1111/j.1365-2265.1994.tb03941.x
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Octreotide Therapy for Thyroid-Stimulating Hormone-Secreting Pituitary Adenomas: A Follow-up of 52 PatientsAnnals of Internal Medicine, 1993
- Octreotide Treatment of AcromegalyAnnals of Internal Medicine, 1992
- Treatment of thyroid-stimulating hormone-secreting adenomas with octreotideMetabolism, 1992
- SMS 201-995 and Thyroid Function in Acromegaly:Hormone and Metabolic Research, 1992
- Thyrotropin-Secreting Pituitary Adenomas: Report of Seven CasesJournal of Clinical Endocrinology & Metabolism, 1991
- Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release propertiesJournal of Microencapsulation, 1990
- Thyrotropin-Secreting Pituitary Adenomas: Clinical and Biochemical HeterogeneityAnnals of Internal Medicine, 1989
- Treatment of Hyperthyroidism due to Inappropriate Secretion of Thyrotropin With the Somatostatin Analog SMS 201–995*Journal of Clinical Endocrinology & Metabolism, 1989
- Response of Thyrotropin-Secreting Pituitary Adenomas to a Long-Acting Somatostatin AnalogueNew England Journal of Medicine, 1987
- Visual Improvement with SMS 201–995 in a Patient with a Thyrotropin-Secreting Pituitary AdenomaNew England Journal of Medicine, 1987